Press

Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder

Jun 2 • 3 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today that they have initiated a larger behavioral addiction study investigating ketamine as a treatment for Gambling Disorder. Awakn announced on May…

Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India

Jun 1 • 2 min read

Clearmind Medicine Inc. (CSE: CMND | OTC Pink: CMNDF | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, has been granted patent approval from the Office of the Controller-General of Patents, Designs and Trademarks in India. The patent refers to the company’s proprietary…

Mydecine Announces Closing of Overnight Marketed Public Offering of Units

May 30 • 3 min read

Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: 0NFA) is pleased to announce that it has closed its previously announced best efforts overnight marketed offering of units through a syndicate of agents led by Stifel Nicolaus Canada Inc. and Roth Canada, Inc. Under the Offering, the Company issued 2,447,130 Units at a…

Small Pharma Shares Business Update Ahead of Annual Financial Results

May 30 • 8 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, provides a business update ahead of its annual financial results for the fiscal year ended February 28, 2022. All references to “$” in this press release refer to Canadian dollars unless otherwise indicated. Strengthening the…

Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

May 27 • 4 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex Life Sciences Inc, a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is based…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441